Jeffrey Campbell Thompson - Faculty Biosketch

Jeffrey Campbell Thompson, MD, MTR

Assistant Professor of Medicine (Pulmonary, Allergy and Critical Care) at the Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center

Chairman, IRB #3 (Oncology IRB), University of Pennsylvania

Department: Medicine

Contact information

221 Stemmler Hall
3450 Hamilton Walk
Philadelphia, PA 19104

Office: 215-898-3168

Email:
jeffrey.thompson@uphs.upenn.edu

Education:
BS (Biomedical Sciences Summa Cum Laude)
Auburn University, 2006.
MD (Medicine)
University of Alabama at Birmingham, 2010.
MS (MTR)
University of Pennsylvania, 2017.

Post-Graduate Training
Intern in Medicine, Hospital of the University of Pennsylvania, 2010-2011.
Resident in Medicine, Hospital of the University of Pennsylvania, 2011-2013.
Chief Medical Resident , University of Pennsylvania, 2013-2014.
Fellow in Pulmonary and Critical Care Medicine, University of Pennsylvania, 2014-2017.

Certifications
Diplomate, American Board of Internal Medicine, Internal Medicine, 2013.
Diplomate, American Board of Internal Medicine, Pulmonary Medicine, 2016.
Diplomate, American Board of Internal Medicine, Critical Care , 2018.

Permanent link

> Perelman School of Medicine > Faculty > Details

Selected Publications

J.C. Thompson, A. Vachani: Could DNA Fragments be the Key to Early Detection of Lung Cancer? Am J. Respir Crit Care Med March 2023.

J.C. Thompson, C. Aggarwal, J. Wong, V. Nimgaonkar, W. Hwang, M. Andronov, D.M. Dibardino, C.T. Huthcinson, K. Ma, A. Lanfranco, E. Moon, A.R. Haas, A.P. Singh, C.A. Ciunci, C.D’Avella, J.V.Cohen, J.M. Bauml, R.B. Cohen, C.J. Langer, A. Vachani, E.L. Carpenter: Plasma genotyping at the time of diagnostic tissue biopsy decreases time to treatment in patients with advanced NSCLC – results from a pilot prospective study. Journal of Thoracic Oncology-Clinical and Research Reports 3((4)), March 2022

J.C Thompson*, E.L. Carpenter*, B.A. Silva, J. Rosenstein, A.L. Chien, K.J. Quin, C.R. Espenschied, A. Mak, L.A. Kiedrowski, M. Lefterova, R.J. Nagy, S.S. Yee, T. Black, A.P. Singh, C.A. Ciunci, J.M. Bauml, R.B. Cohen, C.J. Langer, C. Aggarwal: Serial monitoring of circulating tumor DNA by next generation gene sequencing as a biomarker of response and survival in patients with advanced NSCLC receiving pembrolizumab-based therapy. JCO Precision Oncology 19((5)), Mar 2021

J. Gray, J.C. Thompson, E.L. Carpenter. E. Elkhouly, C. Aggarwal: Plasma cell-free DNA genotyping-from emerging concept to a standard-of-care tool in metastatic non-small cell lung cancer. The Oncologist 26((10)): e1812-e1821, Oct 2021.

C. Aggarwal*, J.C Thompson*, T. Black, S. Katz, R. Fan, S.S Yee, A. Chien, T.L. Evans, J. Bauml, E. Alley, C. Ciunci, A. Berman, R. Cohen, D. Lieberman, K. Majmundar, S.L Savitch, J.D. Morrissette, W. Hwang, K. Elenitoba-Johnson, C.J. Langer, E.L. Carpenter.: Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non–small cell lung cancer. JAMA Oncology 5(2): 173-180, Feb 2019.

Yousefi, M. LaRiviere, E. Cohen, T. Buckingham, S. Yee, T. Black, A.Chien, P. Noel, W. Hwang, S.I. Katz, C. Aggarwal, J.C. Thompson, E.L. Carpenter, D: Combining radiomic phenotypes of non-small cell lung cancer with liquid biopsy data may improve prediction of response to EGFR inhibitors. Scientific Reports 11((1)), May 2021.

J.C. Thompson, C. Davis, C. Deshpande, W. Hwang, S. Jeffries, A. Huang, T.C. Mitchell, C.J. Langer, S.M. Albelda: A gene signature of antigen processing and presentation machinery (APM) predicts response to checkpoint blockade in Non-Small Cell Lung Cancer (NSCLC) and melanoma. Journal for ImmunoTherapy of Cancer 8((2)), Oct 2020.

C. Aggarwal, J.C Thompson, A. Chien, K. Quin, W. Hwang, T. Black, S.S. Yee, T. Christensen, M. LaRiviere, B. Silva, K. Banks, R. Nagy, E. Helman, A. Berman, C.A. Ciunci, A. Singh, J. Wasser, J.M. Bauml, C.J. Langer, R. B. Cohen, E.L. Carpenter: Baseline plasma tumor mutation burden predicts response to pembrolizumab-based therapy in patients with metastatic non-small cell lung cancer. Clinical Cancer Research 26((10)): 2354-2361, May 2020.

J.C. Thompson, W. Hwang, C. Davis, C. Deshpande, S. Jeffries, Y. Rajpurohit, V. Krishna, D. Smirnov, R. Verona, M.V. Lorenzi, C.J. Langer, S.M. Albelda: Gene Signatures of Tumor Inflammation and Epithelial-to-Mesenchymal Transition (EMT) Predict Responses to Immune Checkpoint Blockade in Lung Cancer with High Accuracy. Lung Cancer 139: 1-8, Jan 2020.

C. Aggarwal, C. Davis, R. Mick, J.C. Thompson, S. Ahmed, S. Jeffries, S. Bagley, P. Gabriel, T.L. Evans, J. Bauml, C. Ciunci, E. Alley, J.D. Morrissette, R. Cohen, E.L. Carpenter, C. Langer: Influence of TP53 Mutation on Survival and Transformation to Small Cell Lung Cancer in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer JCO Precision Oncology 2: 1-28, Nov 2018.

J. Kargl, X. Zhu, H. Zhang, G. Yang, T. Riesen, M. Shipley, D. Maeda, J. Zebala, J. Mckay-Fleisch, G. Meredith, A. Mashadi-Hossein, C. Baik, R.H. Pierce, M.W. Redman, J.C. Thompson, S.M. Albelda, H. Bolouri, A.M. Houghton: Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC. JCI Insight 4((24)), Dec 2019.

S.M Obrien, A. Klampatsa, J.C.Thompson, M. Martinez, W. Hwang, A. Rao, J. Standalick, S. Kim, E. Cantu, L. Litzky, S. Singhal, E. Eruslanov, E.K. Moon, S.M. Albelda: Function of Human Tumor Infiltrating Lymphocytes in Early Stage Non-Small Cell Lung Cancer. Cancer Immunology Research 7((6)): 896-909, May 2019.

Klampatsa S. O’Brien, J. C. Thompson, S. A.S. Rao, J.E. Standalick, M. Martinez, M. Liousia, E. Cantu, K. Cengel, E. Moon E, S. Singhal, E.B. Eruslanov, S.M Albelda: Phenotypic and Functional Analysis of Malignant Mesothelioma Tumor-Infiltrating Lymphocytes (TILs). Oncoimmunology 8((9)): e1638211, Jul 2019.

J.C. Thompson, R. Fan, T. Black, G.H. Yu, S.L. Savitch, A. Chien, S. Yee, M. Sen, W. Hwang, S.I. Katz, M. Feldman, A. Vachani, E.L. Carpenter. : Measurement and Immunophenotyping of pleural EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients. Lung Cancer 127(10): 25-33, Jan 2019.

M. Marmarelis, E. Bange, W. Hwang, Y. Yang, J.C. Thompson, J. Rosenbaum, J. Bauml, C.Ciunci, E. Alley, R. Cohen, C. Langer, E. Carpenter, C. Aggarwal: Impact of KRAS and TP53 co-mutations on outcomes following first-line systemic among patient with STK11 mutated advanced NSCLC. JCO Precision Oncology 3, May 2019.

M. Marmarelis, J.C. Thompson, C. Aggarwal, T.L. Evans, E. Carpenter. R.B. Cohen, C.J. Langer, J. Bauml.: Emerging uses of circulating tumor DNA in advanced stage non-small cell lung cancer. Ann Transl Med. 5(18): 380, Sep 2017.

S.J. Bagley, S. Kothari, C. Aggarwal, J. Bauml, E. Alley, T.L Evans, J.A. Kosteva, C. Ciunci, J.C. Thompson, S. Stonehouse-Lee, V.E. Sherry, E. Gilbert, B. Sandy, F. Mutale, G. DiLullo, R.B. Cohen, A. Vachani, C. Langer. : Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab treated patients with advanced non-small cell lung cancer. Lung Cancer 106(4): 1-7, Apr 2017.

S. Katz, M. Hammer, S.J. Bagley, C. Aggarwal, J. Bauml, J.C. Thompson, A.C. Nachiappan, C.B. Simone, C. Langer. : Radiologic pseudoprogression during anti-PD1 therapy for advanced non-small lung cancer. J Thorac Oncol. 13(7): 978-986, Jul 2018.

J. C. Thompson, S.S Yee, A.B. Troxel, S.L. Savitch , R. Fan , D. Balli , D.B. Lieberman, J.D Morrissette, T.L Evans, J. Bauml ,C. Aggarwal, J.A Kosteva, E. Alley, C. Ciunci, R.B. Cohen, S. Bagley, S. Stonehouse-Lee, V.E. Sherry, E. Gilbert, C. Langer, A. Vachani, E. Carpenter: Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA. Clinical Cancer Research 22(23): 5772-5782, Dec 2016.